GEN 004

Drug Profile

GEN 004

Alternative Names: GEN-004; Pneumococcal vaccine - Genocea/PATH/Childrens Hospital Boston; Prophylactic Streptococcus pneumoniae vaccine - Genocea Biosciences; Streptococcus pneumoniae prophylactic vaccine - Genocea/PATH/Childrens Hospital

Latest Information Update: 03 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genocea Biosciences
  • Class Antibacterials; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants; Th17 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Pneumococcal infections

Highest Development Phases

  • Suspended Pneumococcal infections

Most Recent Events

  • 28 Oct 2016 Genocea Biosciences plans a phase II trial in Pneumococcal infections (Prevention, In infants, In toddlers)
  • 09 Jun 2016 GEN 004 is available for licensing as of 09 Jun 2016
  • 05 May 2016 Genocea Biosciences completes a phase II trial in Pneumococcal infections (Prevention in healthy volunteers) in United Kingdom (NCT02116998)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top